Friday, July 10, 2026

Patent intelligence · US

US 10683500

UNA oligomers having reduced off-target effects in gene silencing

granted A61KA61K31/713A61K47/14A61P
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 14
Applicant portfolio 55
Patent details — US 10683500
Jurisdiction
US
Status
granted
Grant date
Jun 16, 2020
Expiration
Jun 11, 2040
Claims
10
CPC classes
A61K, A61K31/713, A61K47/14, A61P
View on Google Patents ↗

Quick answer

US 10683500 (UNA oligomers having reduced off-target effects in gene silencing) is held by ARCTURUS THERAPEUTICS, INC.. Status: granted. Granted Jun 16, 2020. Expires Jun 11, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
10
CPC classes
A61K, A61K31/713, A61K47/14, A61P, A61P25/00, A61P25/02

More from ARCTURUS THERAPEUTICS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12398379

    Compositions and methods for treating ornithine transcarbamylase deficiency

    ARCTURUS THERAPEUTICS, INC. · Expires Aug 21, 2045

    granted
  2. US 12390524

    Compositions and methods for inducing immune responses

    ARCTURUS THERAPEUTICS, INC. · Expires Aug 14, 2045

    granted
  3. US 12351834

    Compositions and methods for the treatment of ornithine transcarbamylase deficiency

    ARCTURUS THERAPEUTICS, INC. · Expires Jul 3, 2045

    granted
  4. US 12290567

    Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates

    ARCTURUS THERAPEUTICS, INC. · Expires May 1, 2045

    granted
  5. US 12286395

    Method of synthesis of an ionizable cationic lipid

    ARCTURUS THERAPEUTICS, INC. · Expires Apr 24, 2045

    granted
  6. US 12220485

    Method of making lipid-encapsulated RNA nanoparticles

    ARCTURUS THERAPEUTICS, INC. · Expires Feb 6, 2045

    granted
  7. US 12220455

    Coronavirus vaccine compositions and methods

    ARCTURUS THERAPEUTICS, INC. · Expires Feb 6, 2045

    granted
  8. US 12178921

    Method of lyophilizing lipid nanoparticles

    ARCTURUS THERAPEUTICS, INC. · Expires Dec 26, 2044

    granted

Frequently asked questions

What is US patent 10683500?

US 10683500 (UNA oligomers having reduced off-target effects in gene silencing) is held by ARCTURUS THERAPEUTICS, INC.. Status: granted. Granted Jun 16, 2020. Expires Jun 11, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10683500?

ARCTURUS THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 55 pharmaceutical patents for this assignee.

When does US 10683500 expire?

Our index shows an expiration date of Jun 11, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.